The aryl hydrocarbon receptor (AHR) is activated by 3-methylcholanthrene (MC), a polycyclic aromatic hydrocarbon, and environmental contaminants, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin. Adrenalectomized (ADX) rats have decreased hepatic AHR protein and lower levels of MC-induced CYP1B1 mRNA. To further characterize the effects of decreased AHR protein and the response to MC in ADX rats, we measured AHR-mediated responses in the liver of SHAM and ADX rats, 6 and 54 h after MC treatment. CYP1A2 mRNA was suppressed by 46-60% four days after ADX in vehicle-treated animals. AHR mRNA was induced 4-fold, 6 h after MC in SHAM rats, but no induction was observed in ADX rats. The MC-induced 7-ethoxyresorufin O-deethylation (EROD) activity in ADX rats was 35% of the activity in the MC-treated SHAM group at 6 h. At 54 h post-treatment, the induction of EROD activity by MC was more pronounced in ADX rats compared to 6 h. To assess the overall capacity for hepatic P450-mediated metabolism, we measured NADPH-cytochrome P450 oxidoreductase (POR) activity. POR activity was decreased by 50% following ADX. We have shown that the response to MC in ADX rats is suppressed for some, but not all, AHR-mediated responses and that reduced POR activity following ADX could contribute to a decreased capacity for P450-dependent metabolism. The current study contributes to our understanding of how adrenal-dependent factors modulate the AHR pathway and the response to MC in vivo.
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The aryl hydrocarbon receptor (AHR) regulates xenobiotic biotransformation via transcriptional control of various drug-metabolizing enzymes (DMEs), including phase I cytochromes P450 (P450) and phase II conjugating enzymes (Mimura and Fujii-Kuriyama, 2003) . Many chemicals bind to the AHR, including the environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), and the model polycyclic aromatic hydrocarbon, 3-methylcholanthrene (MC). These exogenous ligands and their adaptive up-regulation of the CYP1 family of enzymes via the AHR have been well characterized (Denison and Whitlock, 1995) . Functions of the AHR in the absence of exogenous ligand have also been reported (Nguyen and Bradfield, 2008) . CYP1A1 and CYP1B1 are typically extra-hepatic enzymes with negligible basal hepatic expression, which is inducible to varying degrees following activation of the AHR. On the other hand, hepatic CYP1A2 is expressed constitutively but is also inducible following AHR ligand exposure. Both constitutive and inducible CYP1A2 expression is regulated by the AHR, as shown by reduced basal and inducible CYP1A2 in the liver of Ahr-null mice (Tijet et al., 2006) . The activity of P450 enzymes depends on the transfer of electrons from NADPH via NADPH-cytochrome P450 oxidoreductase (POR). In turn, the level of POR can influence the level of P450 activity, as shown in hypophysectomized rats that display decreased microsomal P450 activity that can be restored with the addition of exogenous POR (Waxman et al., 1989) .
The AHR is a cytosolic transcription factor that translocates to the nucleus and heterodimerizes with its nuclear partner, the aryl hydrocarbon receptor nuclear translocator (ARNT), upon ligand activation. The regulation of the receptor itself and the functional impact of changes in the level of the receptor in vivo are not well documented. However, its physiological, adaptive and toxicological importance has been highlighted with evidence from Ahr-null mice showing aberrant hepatic vascular development (Lahvis et al., 2005) and a muted adaptive and toxic response to TCDD exposure (Fernandez-Salguero et al., 1996; Tijet et al., 2006) . With respect to regulation of the receptor, the level of the AHR is altered following exposure to aromatic hydrocarbons, with pronounced depletion of AHR protein in cell culture and in rodent liver (Pollenz, 2002) , whereas induction of AHR mRNA by AHR ligands in vivo has been noted (Franc et al., 2001) . Putative aromatic hydrocarbon response elements (AHREs) have been reported in the 5'-flanking region of the rat AHR gene (Harper et al., 2006) .
Few endogenous regulators of AHR expression have been characterized definitively.
Glucocorticoids are putative endogenous regulators of AHR expression and function in rat liver.
We reported that adrenalectomized (ADX) rats have decreased hepatic AHR protein four days after surgery and lower levels of MC-induced CYP1B1 mRNA relative to SHAM 6 h after treatment (Mullen Grey and Riddick, 2009 ). There are conflicting reports concerning the effect of ADX on the induction of hepatic DMEs by MC. MC-induced aryl hydrocarbon hydroxylase (AHH) activity (Nebert and Gelboin, 1969) and benzo [a] pyrene (B[a]P) metabolism (Bogdanffy et al., 1982) are decreased in the liver of ADX rats compared to SHAM rats. However, MC-
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induced enzyme activity between SHAM and ADX rats has not been elucidated. In addition to influencing hepatic drug metabolism, adrenal glands express constitutive CYP1B1 and inducible CYP1A1 (Bhattacharyya et al., 1995) , and participate in P450-mediated steroidogenesis (Nebert and Russell, 2002) .
We set out to study AHR-dependent up-regulation of hepatic DMEs by MC, or the adaptive response (Schmidt and Bradfield, 1996) , in ADX and SHAM rats, building on our recent demonstration of decreased hepatic AHR protein in ADX rats (Mullen Grey and Riddick, 2009 ). The purpose of this in vivo study was to characterize the functional impact of ADX on hepatic expression of POR and its role in P450-mediated metabolism, as well as AHR-dependent constitutive expression of CYP1A2 and the adaptive response to MC. We hypothesized that the lower level of hepatic AHR protein in ADX rats will result in lowered basal CYP1A2 expression and a compromised adaptive response to MC as assessed with multiple AHR target genes.
8 to Purina Rodent Laboratory Chow No. 5001 and water/saline) and handling for 7 days after arrival in the Division of Comparative Medicine, University of Toronto. Bilateral ADX and SHAM operations were performed at 8 weeks of age by University of Toronto animal surgical technicians. Rats recovered for 4 days following surgery before commencement of the treatment regimen. Following surgery, rats were housed individually in opaque cages to reduce environmental stress. ADX rats received 0.9% sodium chloride in drinking water for the remainder of the study. Body weights were monitored during this time to establish the effectiveness of ADX surgery and to monitor general health status. All animals were cared for in accordance with the principles of the Canadian Council on Animal Care and all animal experimentation was approved by the University of Toronto Animal Care Committee.
To assess the response to aromatic hydrocarbon treatment, groups of four to seven SHAM and ADX rats were treated by gavage with MC (20 mg/kg) or corn oil vehicle at four days after surgery. Liver tissue was collected 6 or 54 h later to quantify expression of several target genes at the mRNA, protein and catalytic activity levels. The liver was processed for RNA isolation and subcellular fractionation as described previously (Timsit et al., 2002) . Briefly, each liver was perfused in situ with 50 ml of ice-cold HEGD buffer (25 mM HEPES, 1.5 mM EDTA, 10% glycerol, 1 mM dithiothreitol, pH 7.4), excised and wet weight was recorded.
Approximately 0.1 g portions of tissue from individual livers were frozen in liquid nitrogen and stored at -70°C for subsequent RNA isolation. The remaining liver was homogenized in 4 volumes of HEGD buffer, and cytosol was prepared by differential centrifugation. Several aliquots of liver cytosol and homogenate were frozen and stored in liquid nitrogen until use.
Microsomes were isolated by differential centrifugation using 100-150 mg of snap frozen liver tissue homogenized in 2 ml of phosphate-buffered KCl (1.15% KCl, 10 mM potassium This article has not been copyedited and formatted. The final version may differ from this version. phosphate, pH 7.4). Microsomal pellets were resuspended in 500 µl of storage buffer (10 mM Tris, 20% glycerol, 1 mM EDTA, pH 7.4) and stored at -70°C until use. Cytosolic, microsomal and homogenate protein concentrations were determined by the method of Bradford (1976) .
Immunoblot analysis. The methods for SDS-polyacrylamide gel electrophoresis, transfer to nitrocellulose membrane, blocking and ECL detection of cytosolic AHR protein are described elsewhere (Mullen Grey and Riddick, 2009 ). For CYP1A1 detection, 2.5 µg of liver homogenate protein was loaded and the anti-CYP1A1 antibody was used at a 1:3,000 dilution in TNT (20 mM Tris, pH 7.4, 150 mM NaCl, 0.1% Tween-20) containing 5% skim milk powder with thimerasol, followed by incubation with a sheep anti-mouse Ig-horseradish peroxidase conjugate at a 1:3,000 dilution in TNT containing 5% skim milk powder with thimerasol. For CYP1A2 detection, 2.5 µg of liver homogenate protein was loaded and the anti-CYP1A2 antibody was used at a 1:40,000 dilution in TNT containing 5% skim milk powder with thimerasol, followed by incubation with a sheep anti-mouse Ig-horseradish peroxidase conjugate at a 1:10,000 dilution in TNT containing 5% skim milk powder with thimerasol. For POR detection, 2 µg of liver homogenate protein was loaded and the anti-POR antibody was used at a 1:1,000 dilution in TNT containing 5% skim milk powder with thimerasol, followed by incubation with a donkey anti-rabbit Ig-horseradish peroxidase conjugate at a 1:5,000 dilution in TNT containing 5% skim milk powder with thimerasol. Following ECL detection of target proteins, relative quantitation was performed by scanning processed films on a HP Scanjet 3970 scanner (Hewlett-Packard Company, Palo Alto, CA) and using IPLabGel software (Signal Analytics, Vienna, VA).
Analysis was performed under optimized conditions for each lot of antibody used; a linear relationship between amount of protein loaded and immunoreactive signal intensity was confirmed.
This article has not been copyedited and formatted. The final version may differ from this version. The RNase inhibitor used for the RT step was RiboLock (80 U). Primers for PCR that were previously or newly designed were verified according to up-to-date published sequences for rat AHR mRNA (Genbank accession number NM_013149), rat CYP1A1 mRNA (Genbank accession number NM_012540), rat CYP1A2 mRNA (Genbank accession number NM_012541), rat CYP1B1 mRNA (Genbank accession number NM_12940), rat POR mRNA (Genbank accession number NM_031576), and rat β-actin mRNA (Genbank accession number NM_031144). Samples were analyzed in triplicate using the ABI Prism 7500 Sequence Detection System. Each PCR reaction was prepared to a final volume of 10 µl, including an optimized amount of input cDNA (derived from 1 or 10 ng RNA), optimized final primer concentration (100-300 nM) and 5 µl of 2X Power SYBR Green Master Mix. The primer sequences are listed in Table 1 . Primers were designed as described previously (Mullen Grey and Riddick, 2009 ).
For AHR and β-actin, the comparative threshold cycle (∆∆Ct) relative quantitation method was employed to calculate the level of mRNA by real-time RT-PCR. The efficiencies of the AHR and β-actin real-time PCR reactions were validated as equivalent (data not shown), as required for accuracy by the ∆∆Ct method used. Cycling conditions were: initial cycle of 2 min at 50°C and 10 min at 95°C, followed by 40 cycles at 95°C for 15 s, 58°C for 15 s and 72°C for 45 s. Ct values for each sample were normalized to β-actin mRNA (∆Ct), and the calibrator sample (∆∆Ct). Relative fold change (RQ) was calculated as 2 -∆∆Ct .
This article has not been copyedited and formatted. The final version may differ from this version. POR enzyme activity. Microsomes (15 µg protein) were assayed at room temperature in 0.5-ml (final volume) incubation mixtures containing 300 mM potassium phosphate (pH 7.7) and 70 µM cytochrome c. Reactions were initiated by the addition of 1 mM NADPH and the rate of cytochrome c reduction was determined spectrophotometrically at 550 nm, based on an extinction coefficient of 21 mM -1 cm -1 (Strobel and Dignam, 1978) .
Statistical Analysis. All data are expressed as means ± S.D. All statistical analyses were performed on the original raw data and not on the percent control data presented in the figures.
Data were analyzed initially using a randomized-design three-way ANOVA to identify significant influences of the three independent variables in a given experiment (variable 1 = surgery; variable 2 = MC treatment; variable 3 = time). Post-hoc analysis for the planned comparisons (surgery effect, treatment effect or time effect) was performed to assess whether there were significant differences between particular groups. Post-hoc tests were Bonferroni corrected for multiple comparisons and were performed using the online tool provided by Graphpad Software (www.graphpad.com). In all cases, a result was considered statistically significant if p < 0.05.
This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 1a) . We confirmed our previous finding that the hepatic level of cytosolic AHR protein was decreased 4 days after surgery where vehicle-treated ADX rats had 25% of the level of AHR protein observed in vehicle-treated SHAM rats (Fig. 1b) . The decreased level of AHR protein in vehicle-treated ADX rats persisted at 6 days after surgery, although some recovery was noted with levels at 65% of time-matched vehicle-treated SHAM rats. The well-documented depletion of hepatic cytosolic AHR protein following ligand exposure (Pollenz, 2002) was observed in both SHAM and ADX rats 6 h after MC treatment but the levels of AHR protein returned to at least vehicle-treated levels 54 h after MC administration.
Measurements of AHR protein in whole liver homogenate yielded similar results to liver cytosol indicating that the depletion by MC was not due only to an alteration of subcellular localization of the AHR (data not shown).
This article has not been copyedited and formatted. The final version may differ from this version. The level of hepatic AHR mRNA is induced in SHAM but not ADX rats 6 h after administration of the AHR agonist MC. Up-regulation of the AHR gene by TCDD in vivo has been reported previously (Franc et al., 2001) . To determine whether MC altered the level of AHR mRNA in rat liver and whether the decrease in AHR protein after ADX had an impact on the response to MC, the level of AHR mRNA was measured by real time RT-PCR (Fig. 2 ).
AHR mRNA was induced 4-fold by MC in the liver of SHAM rats at the 6 h time point. No induction by MC was observed in ADX rats at the early time point. At the later time point, the induction by MC was no longer apparent in SHAM rats and no differences were observed between SHAM and ADX rats following vehicle or MC treatment at this time point.
Hepatic CYP1A1 mRNA and protein induction by MC occurs in both SHAM and ADX rats but the statistical significance of the mRNA induction is not sustained at 54 h. CYP1A1
is an AHR target gene commonly used to confirm activation of the AHR following ligand exposure. We used real-time RT-PCR to measure CYP1A1 mRNA following MC treatment (Fig.   3 ). The level of CYP1A1 mRNA was induced by MC in both SHAM and ADX rats 6 h after treatment by approximately 1200-and 600-fold, respectively. At 54 h, the level of CYP1A1 mRNA in MC-treated SHAM rats returned to vehicle-treated levels. At this later time point, the level of CYP1A1 mRNA in MC-treated ADX rats could be described as intermediate, in that it was not significantly different from the induction observed at 6 h in MC-treated ADX rats or the level observed at 54 h in the vehicle-treated ADX group. CYP1A1 protein was measured in whole liver homogenate using immunoblot analysis with an antibody directed against rat CYP1A1. Representative gel images show a single band migrating at approximately 55 kDa (Fig. 4a) . Consistent with its low basal expression in the liver, CYP1A1 protein was not mRNA by real-time RT-PCR (Fig. 5 ). CYP1A2 mRNA was induced 7-fold in MC-treated ADX rats 6 h after treatment. The level of CYP1A2 mRNA in MC-treated SHAM rats was not significantly different from that observed in MC-treated ADX rats at the early time point. The effect of MC on hepatic CYP1A2 mRNA did not persist at the later time point. We also assessed whether ADX and the accompanying decrease in AHR protein had an impact on the basal level of CYP1A2 mRNA in vehicle-treated rats. Although the data in Fig. 5 showed no significant difference in this regard, we pursued this further by measuring CYP1A2 mRNA levels in an independent set of rats from the "acute study" reported in our previous paper (Mullen Grey and Riddick, 2009 ) in order to increase our statistical power. The experimental and surgical timing in this previous set of rats was identical to the protocol used in the study presented here but CYP1A2 mRNA levels were not previously measured or reported. The level of hepatic CYP1A2 mRNA in vehicle-treated ADX rats in the "acute study" was 40% of vehicle-treated SHAM rats and this difference was statistically significant (p = 0.0399; data not shown).
This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 6b) . Three of the six ADX rats at the 6 h time point and one of the four ADX rats at the 54 h time point had undetectable basal CYP1A2 protein levels. These differences between vehicle-treated SHAM and ADX rats for hepatic CYP1A2 protein did not reach statistical significance at either time point. The induction of CYP1A2 protein was observed in all MCtreated SHAM and ADX rats. There were no differences with respect to the level of MCinducible CYP1A2 protein between SHAM and ADX rats.
Induction of CYP1B1 mRNA by MC is not sustained 54 h after treatment. We previously reported that the induction of CYP1B1 mRNA by MC was suppressed by 50% in ADX rats compared to SHAM 6 h after MC treatment (Mullen Grey and Riddick, 2009 ). Here we report the findings for hepatic CYP1B1 mRNA measured in ADX and SHAM rats 54 h after MC treatment, corresponding to 6 days after surgery (Fig. 7) . The induction of CYP1B1 mRNA by MC in SHAM rats was no longer apparent at 54 h. The level of CYP1B1 mRNA in MC-treated ADX rats at 54 h was 5-fold higher than vehicle-treated animals but this difference was not Induction of hepatic EROD activity by MC is more pronounced at the later time point in ADX rats. The effect of ADX on the induction of CYP1A1 enzyme activity by MC was assessed in rat liver microsomes using an EROD assay (Fig. 8) . At 6 h, EROD activity was induced 10-fold in liver microsomes from MC-treated SHAM rats compared to vehicle-treated rats. The induction by MC in SHAM rats at 54 h was greater, representing a 21-fold induction over the time-matched vehicle-treated SHAM group and a 1.3-fold increase relative to the MCtreated SHAM group at 6 h. The MC-induced EROD activity in ADX rats was 35% of the activity in the MC-treated SHAM group at 6 h. At 54 h post-treatment, the 26-fold induction of EROD activity by MC in ADX rats was more pronounced compared to 6 h. This level of EROD activity represented a 2.5-fold increase over that observed in MC-treated ADX rats at 6 h and was 67% of the level observed in time-matched MC-treated SHAM rats.
Hepatic POR protein and activity are decreased in ADX rats. The level of hepatic POR mRNA was measured by real-time RT-PCR in SHAM and ADX rats following vehicle or MC treatment (Fig. 9) . POR mRNA levels were not altered by surgery or MC treatment. Hepatic migrating at approximately 78 kDa (Fig. 10a) . Treatment with MC did not affect hepatic POR protein in either SHAM or ADX rats at either time point. At the 6 h time point, 4 days after surgery, ADX rats showed a 70% decrease in hepatic POR protein compared to SHAM rats ( Fig.   10b ), whether treated with vehicle or MC. While this effect appeared to persist at the later time point to a varying degree, the difference in POR protein levels between treatment-matched SHAM and ADX rats was only statistically significant at the early time point. Measurement of microsomal cytochrome c reduction was used to assess the hepatic POR activity of SHAM and ADX rats following vehicle or MC treatment (Fig. 11 ). Similar to our hepatic POR protein data, POR catalytic activity was decreased by 50% in ADX rats compared to treatment-and timematched SHAM rats. This difference was statistically significant at both time points and in both vehicle-and MC-treated groups.
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Discussion
We demonstrated that ADX rats differ from their SHAM counterparts in basal hepatic POR protein and activity, constitutive hepatic CYP1A2, and some AHR-mediated responses to MC treatment. This is an important follow-up to our report showing decreased hepatic AHR protein and decreased MC-induced CYP1B1 mRNA at 4 days following ADX (Mullen Grey and Riddick, 2009). We report here that the response to MC was altered for AHR mRNA and CYP1A1 enzyme activity, where the induction in SHAM rats was absent or decreased in ADX rats at the early time point. A delayed response to MC was apparent in ADX rats, whereby CYP1A1 enzyme activity was induced to a greater extent at the later time point. A tendency for a similar delayed, or more pronounced, response at the later time point in ADX rats was also observed for CYP1A1 mRNA and protein, and CYP1B1 mRNA, but these differences were not statistically significant. Hepatic POR protein and enzyme activity were also lower in ADX rats, suggesting an overall diminished capacity for P450-mediated biotransformation. CYP1A2 mRNA, basally regulated by the AHR, was also decreased in vehicle-treated ADX rats when compared to SHAM.
The auto-regulation of AHR mRNA has been shown in rat liver (Kondraganti et al., 2005) whereby one dose of MC induced AHR mRNA. Putative AHREs were identified in the 5'-flanking region of the rat AHR gene (Harper et al., 2006) , suggesting that the gene might be a transcriptional target of the AHR. We showed that 6 h after a single dose of MC, AHR mRNA was induced 4-fold in SHAM rats compared to vehicle; for MC-treated ADX rats, no induction was observed. This lack of AHR mRNA induction coincided with a 75% decrease in hepatic AHR protein observed in ADX rats four days after surgery. In vehicle-treated ADX rats, the The contribution of glucocorticoids to CYP1A2 mRNA regulation appears to occur via alteration of AHR levels caused by ADX and perhaps by potentiation of induction in the presence of exogenous AHR ligands, but evidence for a direct effect of glucocorticoids on CYP1A2 mRNA levels is not apparent.
Compared to the AHR mRNA auto-induction response, we did not observe the same trend of diminished induction by MC in ADX rats for CYP1A1 and CYP1A2 mRNA, both transcriptional targets of the AHR. For CYP1A1, this was surprising given that DEX treatment is known to potentiate CYP1A1 mRNA induction by ß-NF in rat hepatocytes (Sidhu and Omiecinski, 1995) and CYP1A1 induction by MC in rat liver in vivo (Sherratt et al., 1989) .
Glucocorticoid response elements identified in intron 1 of the rat CYP1A1 gene are responsible for the glucocorticoid potentiation effect on AHR-mediated induction, but glucocorticoids alone do not influence the regulation of CYP1A1 (Linder et al., 1999) . The effects of ADX on glucocorticoid-dependent transcriptional responses also depend on timing of steroid However, the impact that lowered AHR protein levels caused by ADX has on MC responsiveness is target-specific, likely owing to differences in mRNA stabilities and/or the specific regulatory milieu for each gene.
Four days after surgery and 6 h after MC, the differences between SHAM and ADX rats suggest that ADX has important functional impacts on hepatic drug metabolism. The level of hepatic POR activity was decreased in ADX rats relative to treatment-matched SHAM rats and the induction of hepatic CYP1A1 enzyme activity by MC was decreased in ADX rats. For hepatic CYP1A1 protein, the fold-induction by MC relative to vehicle was not reported because immunoreactive protein in vehicle-treated samples was undetectable. The level of hepatic CYP1A1 immunoreactive protein in MC-treated ADX rats was 50% of levels in MC-treated SHAM rats. This difference was not statistically significant but the functional impact was pronounced for the difference in MC-induced CYP1A1 enzyme activity between ADX and SHAM rats. It is likely that the compromised hepatic CYP1A1 enzyme activity in ADX rats at 6 h is partly due to decreased POR activity and to the trend for decreased CYP1A1 protein in MCtreated ADX rats. The level of POR activity influences the capacity for P450-dependent catalysis; for example, hepatic POR activity is decreased in hypophysectomized rats and consequently, P450-dependent catalytic activity is compromised (Waxman et al., 1989) . The
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As mentioned above, certain early responses (6 h) to MC in ADX rats were impaired in comparison to SHAM rats. However, assessments at 54 h indicated that the response to MC was either delayed or more pronounced in ADX rats. While decreased induction of CYP1A1 enzyme activity was observed 6 h after MC in ADX rats, the induction of CYP1A1 enzyme activity by MC at 54 h was more pronounced, despite the decrease in POR activity sustained in ADX rats at this time. Hepatic levels of MC drop to less than 1% of administered dose 14 h after a single treatment (Bresnick et al., 1967) . This rapid hepatic clearance of MC is due in large part to biotransformation by P450 enzymes; CYP1A1 and CYP1B1 are primarily responsible for metabolism of MC-like polycyclic aromatic hydrocarbons, following induction (Shimada, 2006).
We hypothesize that at the early time point, down-regulation of constitutive P450s (e.g. CYP2C11) (Murray, 2000) , lower MC-induced CYP1A1 activity, and lower POR activity, all act to slow the hepatic clearance of MC in ADX rats relative to SHAM rats. Consequently, higher hepatic levels of parent MC may persist in ADX rats leading to activation of AHR protein, present at recovering levels at the 54 h time point.
Although not yet confirmed in our experiments, this slower clearance could account for the delayed MC induction profile in ADX rats, as shown for CYP1A1 enzyme activity, with a similar trend observed for CYP1A1 mRNA, CYP1A1 protein and CYP1B1 mRNA.
This article has not been copyedited and formatted. The final version may differ from this version. There is some published evidence that ADX decreases hepatic POR activity (Castro et al., 1970; Sherratt et al., 1989) . Cortisone acetate (5 mg/kg/day x 8 days) restores hepatic POR activity in ADX rats (Castro et al., 1970) . DEX (10 mg/kg/day x 2 days) increases hepatic POR activity in SHAM and ADX rats (Sherratt et al., 1989) and DEX (10 mg/kg single dose)
increases hepatic POR activity in neonatal and adolescent rats (Linder and Prough, 1993) . Higher doses of DEX (80 mg/kg) induced hepatic POR mRNA, apparently via mRNA stabilization (Simmons et al., 1987) . Such doses of DEX, however, might activate the pregnane X receptor, which is activated by DEX at concentrations higher than those required for glucocorticoid receptor (GR) activation (Zhang et al., 1999) . POR mRNA levels were not decreased by ADX under the conditions of this experiment, but since the mRNA for TAT, a prototypical GRregulated gene, was not decreased by ADX (Mullen Grey and Riddick, 2009), the glucocorticoid regulation of the rat POR gene cannot be excluded. Our preliminary data suggest that low doses of DEX induce rat hepatic POR mRNA (data not shown). We are currently studying the role of the GR in this response.
In conclusion, we have demonstrated that: (1) in ADX rats showing decreased hepatic AHR protein levels, basal hepatic CYP1A2 mRNA, MC-induced AHR mRNA and EROD activity are suppressed; (2) the induction of hepatic CYP1A1 enzyme activity by MC is more pronounced at the later time point in ADX rats; and (3) ADX rats have decreased hepatic POR protein and activity. This study contributes to our understanding of how adrenal-dependent factors modulate the hepatic AHR pathway and the response to MC and related environmental contaminants in vivo.
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